-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $12

Benzinga·05/02/2025 16:26:41
Listen to the news
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $18 to $12.